South Korea-based healthcare company Yuyu Pharma announced on Tuesday that it has completed a strategic investment in Dalan Animal Health, a US-based biotechnology company advancing an innate immunity-based platform for developing vaccines for honeybees and shrimp.
This investment will enable the company to continue to expand its platform across new species, exploring novel applications for poultry as well as other aquaculture species.
Robert Wonsang Yu, CEO of Yuyu Pharma, said: "Yuyu Pharma is moving decisively into new areas of animal health where scientific innovation can create lasting global impact. Bees, shrimp, and other essential species play foundational roles in food systems and environmental stability. Our investment in Dalan reflects a clear ambition: to engage directly with technologies that will shape the next generation of global animal health solutions."
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action
AstraZeneca launches online platform to expand patient access to medications